Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Article
  • Open Access

31 March 2025

21 Pages

Prognostic Value of SOX2 and NANOG Expression in Recurrent Oral Squamous Cell Carcinoma

,
,
,
,
,
,
,
,
and
1
Department of Oral and Maxillofacial Surgery, Head and Neck Cancer Center, University Hospital Schleswig-Holstein, 23562 Lübeck, Germany
2
Department of Internal Medicine II, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany
3
Derby Clinical Trials Support Unit, University Hospitals of Derby and Burton NHS Foundation Trust, Derby DE22 3NE, UK
4
Institute of Pathology, University Hospital Schleswig-Holstein, 23562 Lübeck, Germany
This article belongs to the Special Issue Head and Neck Cancer Metastases

Simple Summary

Recurrent oral squamous cell carcinoma often leads to poor outcomes and limited treatment options. In this study, we examined two proteins, SOX2 and NANOG, which are involved in the growth and survival of cancer stem cells. We analyzed tumor samples from 94 patients to assess how the levels of these proteins change between the primary tumor and the recurrence, and whether these changes are linked to patient survival. We found that higher levels of SOX2 in recurrent tumors were associated with better survival. In contrast, NANOG levels decreased in recurrent tumors, especially in patients treated with surgery alone, but this decrease was not significantly associated with survival outcomes. These findings suggest that SOX2 could serve as a valuable marker for predicting prognosis in patients with recurrent oral squamous cell carcinoma. Identifying such markers may support more personalized treatment decisions and ultimately improve care for patients facing this aggressive disease.

Abstract

Background: Recurrent oral squamous cell carcinoma (re-OSCC) poses a serious therapeutic challenge and is linked to poor survival outcomes. SOX2 and NANOG, key transcription factors in cancer stem cell biology, may drive tumor progression and therapy resistance. However, their prognostic value in re-OSCC and their relationship to adjuvant therapy remain unclear. Methods: We retrospectively analyzed a single-center cohort of 94 patients with re-OSCC treated with curative intent via (1) surgery alone, (2) surgery plus adjuvant radiotherapy (RT), or (3) surgery plus adjuvant radiochemotherapy (RCT). Tissue microarrays (TMAs) were constructed from matched primary and recurrent tumors and immunohistochemical (IHC) staining for SOX2, and NANOG was quantified using H-scores. Post-recurrence overall survival (prOS) and post-recurrence disease-free survival (prDFS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards models. Results: SOX2 expression and survival: Elevated SOX2 expression (H-score > 14) in re-OSCC was significantly associated with improved prOS (p = 0.013) and prDFS (p = 0.026). Notably, patients who had received adjuvant therapy (particularly RCT) showed higher SOX2 levels in recurrent tumors compared to those treated with surgery alone. NANOG expression and therapy: NANOG expression declined markedly from primary to recurrent tumors (median H-score 42.2 vs. 8.7; p < 0.001). This decline was most pronounced in patients treated with surgery alone. Despite this dynamic change, NANOG expression did not correlate significantly with prOS or prDFS. Other prognostic factors include advanced tumor stage (rT2–rT4) and lymph node involvement (rN+/x)m which remained significant predictors of worse survival in the recurrent setting, regardless of adjuvant therapy. Conclusion: SOX2 overexpression in re-OSCC correlates with better survival, suggesting a unique prognostic role distinct from primary disease. Adjuvant therapy, especially RCT, appears to maintain or elevate SOX2 levels, potentially contributing to improved treatment response. In contrast, although NANOG expression decreases in recurrence, particularly in patients who undergo surgery alone, it does not significantly affect survival outcomes. These findings underscore the importance of context-specific biomarker assessments and provide a rationale for incorporating SOX2 status into personalized treatment strategies for re-OSCC.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.